Epigenetics in disease and cancer

Malaysian Journal of Pathology

Volumn 33, Issue 2, 2011, Pages 61-70

  Choo, Kong Bung ^a  

^a UNIVERSITI TUNKU ABDUL RAHMAN   (Malaysia)

Author keywords

Cancer; Chromatin modification; Disease; DNA methylation; Epigenetics; Gene expression; MicroRNA

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; MICRORNA; SMALL INTERFERING RNA; TUMOR MARKER; UNTRANSLATED RNA; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BIOLOGICAL ACTIVITY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GENE THERAPY; CANCER GENETICS; CARCINOGENESIS; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHRONIC MYELOID LEUKEMIA; CPG ISLAND; CUTANEOUS T CELL LYMPHOMA; DEACETYLATION; DIAGNOSTIC VALUE; DNA HELIX; DNA METHYLATION; DNA REPLICATION; DRUG MECHANISM; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; GENE MUTATION; GENE SILENCING; HEMATOLOGIC MALIGNANCY; HISTONE MODIFICATION; HUMAN; MYELODYSPLASTIC SYNDROME; NONHUMAN; POLYMERASE CHAIN REACTION; PROMOTER REGION; REGULATOR GENE; REVIEW; RNA INTERFERENCE; TRANSCRIPTION REGULATION;

ANIMALS; EPIGENESIS, GENETIC; HUMANS; NEOPLASMS;

EID: 84855303734     PISSN: 01268635     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Caffarelli E, Filetici P. Epigenetic regulation in cancer development. Front Biosci 2011;17:2682-94
2. Chandrasekharan MB, Huang F, Sun ZW. Histone H2B ubiquitination and beyond: Regulation of nucleosome stability, chromatin dynamics and the trans-histone H3 methylation. Epigenetics 2010;5:460-8
3. Hargreaves DC, Crabtree GR. ATP-dependent chromatin remodeling: genetics, genomics and mechanisms. Cell Res 2011;21:396-420
4. Lister R, Ecker JR. Finding the fifth base: genomewide sequencing of cytosine methylation. Genome Res 2009;19:959-66
5. Tahiliani M, Koh KP, Shen Y, et al. Conversion of 5-methylcytosine to 5-hydroxy- methylcytosine in mammalian DNA by MLL partner TET1. Science 2009;324:930-5
6. Kriaucionis S, Heintz N. The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science 2009;324:929-30
7. Fernandez AF, Assenov Y, Martin-Subero JI, et al. A DNA methylation fingerprint of 1628 human samples. Genome Res 2011; Jul 12, 2011 [Epub ahead of print]
8. Hinoue T, Weisenberger DJ, Lange CP, et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res 2011, Jun 9, 2011 [Epub ahead of print]
9. Gupta R, Nagarajan A, Wajapeyee N. Advances in genome-wide DNA methylation analysis. Biotechniques 2010:49:iii-xi
10. Shames DS, Minna JD, Gazdar AF. Methods for detecting DNA methylation in tumors: from bench to bedside. Cancer Lett 2007;251:187-98
11. Chen ST, Choo KB, Hou MF, et al. Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. Carcinogenesis 2005;26:1241-6
12. Villeneuve LM, Natarajan R. Epigenetic mechanisms. Contrib Nephrol 2011;170:57-65
13. Sugii S, Evans RM. Epigenetic codes of PPARgamma in metabolic disease. FEBS Lett 2011;585:2121-8
14. Ling C, Groop L. Epigenetics: a molecular link between environmental factors and type 2 diabetes. Diabetes 2009;58:2718-25
15. Hsu MC, Huang CC, Choo KB, Huang CJ. Uncoupling of promoter methylation and expression of Period1 in cervical cancer cells. Biochem Biophys Res Commun 2007;360:257-62
16. Tokita T, Maesawa C, Kimura T, et al. Methylation status of the SOCS3 gene in human malignant melanomas. Int J Oncol 2007;30:689-94
17. De Smet C, Loriot A. DNA hypomethylation in cancer: Epigenetic scars of a neoplastic journey. Epigenetics 2010;5: doi:11447[pii]
18. Robertson KD. DNA methylation and human disease. Nat Rev Genet 2005;6:597-610
19. Aguilera O, Fernandez AF, Munoz A, Fraga MF. Epigenetics and environment: a complex relationship. J Appl Physiol 2010;109:243-51
20. Christensen BC, Houseman EA, Marsit CJ, et al. Aging and environmental exposures alter tissuespecific DNA methylation dependent upon CpG island context. PLoS Genet 2009;5:e1000602
21. Jones PA, Baylin SB.The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-28
22. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006;6:107-16
23. Soltanian S, Matin MM. Cancer stem cells and cancer therapy. Tumour Biol 2011;32:425-40
24. Alison MR, Islam S, Wright NA. Stem cells in cancer: instigators and propagators? J Cell Sci 2010;123:2357-68
25. Tsai HC, Baylin SB. Cancer epigenetics: linking basic biology to clinical medicine. Cell Res 2011; 21:502-17
26. Nishino K, Toyoda M, Yamazaki-Inoue M, et al. DNA methylation dynamics in human induced pluripotent stem cells over time. PLoS Genet 2011;7:e1002085
27. Ohi Y, Qin H, Hong C, et al. Incomplete DNA methylation underlies a transcriptional memory of somatic cells in human iPS cells. Nat Cell Biol 2011;13:541-9
28. Topczewska JM, Postovit LM, Margaryan NV, et al. Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness. Nat Med 2006;12:925-32
29. Zilberman D. The human promoter methylome. Nat Genet 2007;39:442-3
30. Kang Y, Massague J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 2004;118:277-9
31. Hendrix MJ, Seftor EA, Seftor RE, et al. Reprogramming metastatic tumour cells with embryonic microenvironments. Nat Rev Cancer 2007;7:246-55
32. Coppieters N, Dragunow M. Epigenetics in Alzheimer's Disease: A Focus on DNA Modifications. Curr Pharm Des 2011;doi:BSP/CPD/EPub/ 000707[pii]
33. Bell CG, Finer S, Lindgren CM, et al. Integrated genetic and epigenetic analysis identifies haplotype-specific methylation in the FTO type 2 diabetes and obesity susceptibility locus. PLoS One 2010;5:e14040
34. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993;75:843-54
35. Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998;391:806-11
36. Webster RJ, Giles KM, Price KJ, et al. Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J Biol Chem 2009;284:5731-41
37. Mohri T, Nakajima M, Takagi S, Komagata S, Yokoi T. MicroRNA regulates human vitamin D receptor. Int J Cancer 2009;125:1328-33
38. Oberg AL, French AJ, Sarver AL, et al. miRNA expression in colon polyps provides evidence for a multihit model of colon cancer. PLoS One 2011;6:e20465
39. Git A, Dvinge H, Salmon-Divon M, et al. Systematic comparison of microarray profiling, real-time PCR, and next-generation sequencing technologies for measuring differential microRNA expression. RNA 2010;16:991-1006
40. Schetter AJ, Leung SY, Sohn JJ, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma, JAMA 2008;299:425-36
41. Bueno MJ, Malumbres M. MicroRNAs and the cell cycle. Biochim Biophys Acta 2011;1812:592-601
42. Zimmerman AL, Wu S. MicroRNAs, cancer and cancer stem cells. Cancer Lett 2011;300:10-9
43. Sun X, Fu X, Han W, Zhao Y, Liu H. Can controlled cellular reprogramming be achieved using microRNAs? Ageing Res Rev 2010;9:475-83
44. Jiang J, Lee EJ, Gusev Y, Schmittgen TD. Realtime expression profiling of microRNA precursors in human cancer cell lines. Nucleic Acids Res 2005;33:5394-403
45. Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007;302:1-12
46. Durkin SG, Glover TW. Chromosome fragile sites. Annu Rev Genet 2007;41:169-92
47. Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004;101:2999-3004
48. Yamanaka S. A fresh look at iPS cells. Cell 2009;137:13-7
49. Li Z, Yang CS, Nakashima K, Rana TM. Small RNA-mediated regulation of iPS cell generation. EMBO J 2011;30:823-34
50. Subramanyam D, Lamouille S, Judson RL, et al. Multiple targets of miR-302 and miR-372 promote reprogramming of human fibroblasts to induced pluripotent stem cells. Nat Biotechnol 2011;29:443-8
51. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008;105:10513-8
52. Slaby O, Svoboda M, Michalek J, Vyzula R. MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol Cancer 2009;8:102
53. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis 2010;31:27-36
54. Plimack ER, Kantarjian HM, Issa JP. Decitabine and its role in the treatment of hematopoietic malignancies. Leuk Lymphoma 2007;48:1472-81
55. Datta J, Ghoshal K, Denny WA, et al. A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation. Cancer Res 2009;69:4277-85
56. Cortez CC, Jones PA. Chromatin, cancer and drug therapies. Mutat Res 2008;647:44-51
57. Pang M, Zhuang S. Histone deacetylase: a potential therapeutic target for fibrotic disorders. J Pharmacol Exp Ther 2010;335:266-72
58. Carew JS, Giles FJ, Nawrocki ST. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 2008;269:7-17
59. Sebova K, Fridrichova I. Epigenetic tools in potential anticancer therapy. Anticancer Drugs 2010;21:565-77
60. Kristensen LS, Nielsen HM, Hansen LL. Epigenetics and cancer treatment. Eur J Pharmacol 2009;625:131-42
61. Saito Y, Liang G, Egger G, et al. Specific activation of microRNA-127 with downregulation of the protooncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006;9:435-43
62. Friedman JM, Liang G, Liu CC, et al. The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res 2009;69:2623-9